Akebia Therapeutics (AKBA) Research & Development: 2017-2025
Historic Research & Development for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $14.9 million.
- Akebia Therapeutics' Research & Development rose 76.08% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 32.93%. This contributed to the annual value of $37.7 million for FY2024, which is 40.31% down from last year.
- Akebia Therapeutics' Research & Development amounted to $14.9 million in Q3 2025, which was up 35.69% from $11.0 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Research & Development peaked at $43.8 million during Q1 2022, and registered a low of $7.6 million during Q2 2024.
- Its 3-year average for Research & Development is $12.4 million, with a median of $11.0 million in 2025.
- As far as peak fluctuations go, Akebia Therapeutics' Research & Development slumped by 69.27% in 2023, and later soared by 76.08% in 2025.
- Akebia Therapeutics' Research & Development (Quarterly) stood at $29.6 million in 2021, then rose by 8.60% to $32.1 million in 2022, then slumped by 69.27% to $9.9 million in 2023, then grew by 19.47% to $11.8 million in 2024, then surged by 76.08% to $14.9 million in 2025.
- Its last three reported values are $14.9 million in Q3 2025, $11.0 million for Q2 2025, and $9.8 million during Q1 2025.